CeNeRx BioPharma, Inc., a biopharmaceutical company developing and commercializing innovative treatments for diseases of the central nervous system, today announced it has signed an agreement with PharmaNess Neuroscience giving CeNeRx the rights to a series of novel cannabinoid compounds that selectively target the CB1 and CB2 cannabinoid receptors.
From: biz.yahoo.com
Wednesday, May 30, 2007
CeNeRx Announces Agreement With PharmaNess Neuroscience to Develop Novel Cannabinoid Compounds
Subscribe to:
Post Comments (Atom)
![Digitalpoint Geo Tracking [Enabled]](http://geo.digitalpoint.com/a.png)
![PingOmatic AutoDiscovery [Enabled]](http://www.genuineblogger.com/images/chicklet-pingomatic.gif)
![Made with Palestinian Efforts [True]](http://www.genuineblogger.com/images/yapalestinets.gif)
No comments:
Post a Comment